MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
1.100
+0.010
+0.92%
After Hours: 1.082 -0.018 -1.66% 19:24 05/24 EDT
OPEN
1.080
PREV CLOSE
1.090
HIGH
1.120
LOW
1.080
VOLUME
1.64M
TURNOVER
0
52 WEEK HIGH
2.480
52 WEEK LOW
0.7801
MARKET CAP
230.56M
P/E (TTM)
-4.9706
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AKBA last week (0520-0524)?
Weekly Report · 11h ago
Weekly Report: what happened at AKBA last week (0513-0517)?
Weekly Report · 05/20 10:33
Weekly Report: what happened at AKBA last week (0506-0510)?
Weekly Report · 05/13 10:40
AKBA Stock Earnings: Akebia Therapeutics Misses EPS, Misses Revenue for Q1 2024
Akebia Therapeutics reported earnings per share of -9 cents for the first quarter of 2024. The company reported revenue of $32.61 million. This was below the analyst estimate of $46.34 million. Akebia TherAPEutics is a biopharmaceutical company.
Investorplace · 05/09 15:57
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/09 12:10
Akebia Therapeut: Current report
Press release · 05/09 12:04
Akebia GAAP EPS of -$0.09 misses by $0.01, revenue of $32.6M misses by $13.49M
Q1 GAAP EPS of -$0.09 misses by $0.01, revenue of $32.6M misses by 18.8% Y/Y. Akebia Therapeutics, Inc. Is expected to report its results on May 9, 2024.
Seeking Alpha · 05/09 11:21
AKEBIA THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Reuters · 05/09 11:00
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.